- Xcell Biosciences has announced a strategic collaboration with Thermo Fisher Scientific to advance cell therapy research focused on Tregs and TILs.
- The partnership will leverage both companies’ technologies to enhance efficacy, scalability, and manufacturing workflows.
Xcell Biosciences, a San Francisco-based cell and gene therapy instrumentation company, has entered into a collaboration with Thermo Fisher Scientific to drive advancements in regulatory T cell (Treg) and tumor-infiltrating lymphocyte (TIL) research.
The partnership aims to develop new methodologies that improve the therapeutic potential of Tregs and TILs, which are increasingly being explored for treating autoimmune diseases and solid tumours. The collaboration also focuses on improving the scalability and reproducibility of cell therapy manufacturing, a critical step toward broader clinical access.
Xcell Biosciences will contribute its AVATAR™ platform, while Thermo Fisher will offer its Gibco™ CTS™ tools, including the Detachable Dynabeads™, DynaCellect™ Magnetic Separation System, and the Rotea™ Centrifugation System. The companies aim to enhance the speed and quality of manufacturing workflows for advanced therapies.
“We are thrilled to collaborate with Thermo Fisher Scientific on groundbreaking research opportunities,” said Shannon Eaker, chief technology officer at Xcell Biosciences.
“Xcellbio’s use of our Detachable Dynabeads™ within Thermo Fisher’s automated cell therapy workflow reflects the strength of our technologies,” said Andy Campbell, senior director of R&D at Thermo Fisher Scientific. “Together with our DynaCellect™ and Rotea™ systems, this collaboration aims to streamline manufacturing and support better patient outcomes.”
Stay ahead of trends and best practices
